Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 6/20 | 0.53 |
| ▸ | FLT3 | P36888 | 3/20 | 0.52 |
| ▸ | KIT | P10721 | 2/20 | 0.52 |
| ▸ | ABL1 | P00519 | 10/20 | 0.48 |
| ▸ | LYN | P07948 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | SIK2 | Q9H0K1 | 11/20 | 0.46 |
| ▸ | SIK3 | Q9Y2K2 | 11/20 | 0.46 |
| ▸ | SIK1 | P57059 | 9/20 | 0.46 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19928686 | 0.89 | SRC (0.56) | SRCFLT3KITABL1LYN | |
| SCHEMBL16809275 | 0.82 | SRC (0.56) | SRCFLT3KITABL1LYN | |
| SCHEMBL19928672 | 0.80 | CASP1 (0.40) | SRCFLT3KITABL1AURKA | |
| SCHEMBL24122681 | 0.79 | SRC (0.53) | SRCFLT3KITABL1LYN | |
| SCHEMBL17469517 | 0.78 | SRC (0.53) | SRCFLT3KITABL1LYN | |
| SCHEMBL21952671 | 0.78 | SRC (0.53) | SRCFLT3KITABL1LYN | |
| SCHEMBL11960310 | 0.77 | SRC (0.48) | SRCFLT3KITABL1LYN | |
| SCHEMBL10064870 | 0.77 | SRC (0.52) | SRCFLT3KITABL1LYN | |
| SCHEMBL11981518 | 0.76 | SORD (0.57) | SRCFLT3KITABL1LYN | |
| SCHEMBL2237335 | 0.74 | SRC (0.47) | SRCFLT3KITABL1LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908872-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |